Frederick Locke, MD
Hematology & Oncology · Tampa, FLNPI 1518129121
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,704 of the $116,611 with a category attached, or 62.3%. 17 manufacturers reported payments, led by Gilead at 46.5% of the total. Reporting peaked in 2023 at $41,435 and has fallen 76.1% since, to $9,911 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $1005.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$54K
- Bristol Myers Squibb$15K
- E.r. Squibb & Sons, L.L.C.$10K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Pfizer$6K
- Amgen$6K
- plus $17K from 11 others
Across 657 payments — averaging $19,334 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$12.2M
- Regeneron$224K
- Bristol Myers Squibb$211K
- Incyte Corporation$64K
- Institut DE Recherches Internationales Servier$26K
- Novartis$15K
What the payments were for
- Consulting fees$72,70462%
- Speaking & faculty fees$10,7199%
- Grants$1550%
- Travel & lodging$27,83624%
- Food & beverage$4,1394%
- Education$1,0571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 42 | $54,266 |
| Bristol Myers Squibb | 16 | $14,891 |
| E.r. Squibb & Sons, L.L.C. | 5 | $10,359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $7,588 |
| Pfizer | 3 | $6,030 |
| Amgen | 2 | $6,000 |
| Novartis | 31 | $4,358 |
| Janssen Scientific Affairs, LLC | 1 | $4,000 |
| Iovance Biotherapeutics, Inc. | 2 | $2,848 |
| Adaptive Biotechnologies Corporation | 1 | $2,400 |
| Adaptimmune LLC | 1 | $1,630 |
| Incyte Corporation | 2 | $1,125 |
| Janssen Global Services, LLC | 1 | $775 |
| Sanofi | 1 | $155 |
| Legend Biotech USA Inc. | 1 | $88 |
| EUSA Pharma (US) LLC | 1 | $74 |
| ADC Therapeutics America, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,611 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.